ストックスクリーナーアプリを入手
6.79
6.23%
0.37
アフターアワーズ：
6.58
-0.21
-3.09%
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns “Buy” Rating from HC Wainwright - Defense World
CRBP stock touches 52-week low at $6.53 amid sharp annual decline - Investing.com Australia
CRBP stock touches 52-week low at $6.53 amid sharp annual decline By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Jefferies Financial Group Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - Defense World
Dermatomyositis Treatment Market Size Report 2034 | - openPR
Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
2 Top Resilient Stocks to Buy on Trump Tariffs Dialing Into Strength - The Globe and Mail
Corbus Pharmaceuticals Advances in Oncology and Obesity - TipRanks
Corbus Pharmaceuticals: Q4 Earnings Snapshot - mySA
Corbus Pharmaceuticals Holdings Inc. (CRBP) reports earnings - Quartz
SEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc. - Quantisnow
Corbus Pharmaceuticals Holdings, Inc. SEC 10-K Report - TradingView
Corbus Pharmaceuticals Reports Q4 2024 Financial Results - TipRanks
Corbus Pharmaceuticals' cash runway expected through third-quarter 2027 -March 11, 2025 at 09:33 am EDT - Marketscreener.com
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Corbus Pharmaceuticals: Q4 Earnings Snapshot -March 11, 2025 at 08:18 am EDT - Marketscreener.com
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Earnings: FDA Fast Track Status Powers $149M Cash Runway Through 2027 - StockTitan
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Raised to Sell at StockNews.com - Defense World
Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Brokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $61.38 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch
When (CRBP) Moves Investors should Listen - Stock Traders Daily
CRBP stock touches 52-week low at $7.22 amid sharp yearly decline - Investing.com India
CRBP stock touches 52-week low at $7.22 amid sharp yearly decline By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ:CRBP) Research Coverage Started at William Blair - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Outperform Rating from Analysts at William Blair - MarketBeat
William Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform Recommendation - MSN
William Blair Initiates Corbus Pharmaceuticals at Outperform -February 28, 2025 at 07:57 am EST - Marketscreener.com
Corbus presents new cancer drug study at ASCO GU - MSN
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Can Corbus' Dual Focus on Oncology and Obesity Attract Investor Attention? CEO Set for Conference Circuit - StockTitan
Invalidations Everywhere… Except in Gold - The Globe and Mail
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
How To Trade (CRBP) - Stock Traders Daily
Dermatomyositis Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Treatment Market, Medication, Revenue, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
CRBP stock touches 52-week low at $7.87 amid market challenges By Investing.com - Investing.com South Africa
CRBP stock touches 52-week low at $7.87 amid market challenges - Investing.com India
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) Given “Buy” Rating at HC Wainwright - Defense World
Corbus Pharmaceuticals CEO Yuval Cohen sells shares worth $62,464 By Investing.com - Investing.com Australia
Corbus Pharmaceuticals CEO Yuval Cohen sells shares worth $62,464 - Investing.com India
Corbus Pharmaceuticals CFO Sean Moran sells $24,446 in stock - Investing.com India
Corbus Pharmaceuticals CFO Sean Moran sells $24,446 in stock By Investing.com - Investing.com Nigeria
Corbus Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
0.57%
大文字化:
|
ボリューム (24 時間):